+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tourette Syndrome - Pipeline Review, H2 2020

  • ID: 5137250
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 74 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • H. Lundbeck AS
  • SOM Biotech SL
  • MORE
Tourette Syndrome - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2020, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • H. Lundbeck AS
  • SOM Biotech SL
  • MORE
  • Introduction
  • Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Catalyst Pharmaceuticals Inc
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • H. Lundbeck AS
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • Tourette Syndrome - Drug Profiles
  • alpha-dihydrotetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevantolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPP-115 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • deutetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Tourette Syndrome, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, H2 2020
  • Tourette Syndrome - Pipeline by Asarina Pharma AB, H2 2020
  • Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2 2020
  • Tourette Syndrome - Pipeline by Emalex Biosciences Inc, H2 2020
  • Tourette Syndrome - Pipeline by Evero Health Ltd, H2 2020
  • Tourette Syndrome - Pipeline by H. Lundbeck AS, H2 2020
  • Tourette Syndrome - Pipeline by SOM Biotech SL, H2 2020
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
  • Tourette Syndrome - Dormant Projects, H2 2020
  • Tourette Syndrome - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Tourette Syndrome, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Catalyst Pharmaceuticals Inc
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • H. Lundbeck AS
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll